secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001104659-23-109423
Event type: regulatory
Sentiment:  negative
Materiality: 1.00
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx receives Nasdaq delisting notice; trading suspended Oct 16, shares to OTC
-------------------------------------------------------------------------------

- Nasdaq notified Eloxx on Oct 12, 2023 that it failed to regain compliance with $35M MVLS rule.
- Trading of common stock (ELOX) suspended on Nasdaq effective Oct 16, 2023; will trade OTC under same symbol.
- Company intends to request review by Nasdaq Listing Council, which stays delisting filing but not suspension.
- Previously granted extensions expired Oct 9, 2023; stock has been below compliance threshold for over a year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923109423/0001104659-23-109423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923109423/tm2328531d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-109423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer